First Time Loading...

Adaptive Biotechnologies Corp
NASDAQ:ADPT

Watchlist Manager
Adaptive Biotechnologies Corp Logo
Adaptive Biotechnologies Corp
NASDAQ:ADPT
Watchlist
Price: 2.89 USD 0.35%
Updated: Mar 28, 2024

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Adaptive Biotechnologies Corp

Revenue
170.3m USD
Cost of Revenue
-75.6m USD
Gross Profit
94.7m USD
Operating Expenses
-296.3m USD
Operating Income
-201.6m USD
Other Expenses
-23.6m USD
Net Income
-225.3m USD

Margins Comparison
Adaptive Biotechnologies Corp Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
US
Adaptive Biotechnologies Corp
NASDAQ:ADPT
419.3m USD
56%
-118%
-132%
US
Thermo Fisher Scientific Inc
NYSE:TMO
224B USD
40%
17%
14%
US
Danaher Corp
NYSE:DHR
183.9B USD
59%
22%
20%
US
IQVIA Holdings Inc
NYSE:IQV
45.8B USD
35%
14%
9%
KR
Samsung Biologics Co Ltd
KRX:207940
59.3T KRW
49%
30%
23%
US
Agilent Technologies Inc
NYSE:A
43.2B USD
51%
19%
18%
CH
Lonza Group AG
SIX:LONN
39.4B CHF
36%
20%
10%
US
West Pharmaceutical Services Inc
NYSE:WST
29B USD
38%
24%
20%
US
Mettler-Toledo International Inc
NYSE:MTD
28.8B USD
59%
29%
21%
IE
ICON PLC
NASDAQ:ICLR
27.2B USD
30%
13%
8%
FR
Sartorius Stedim Biotech SA
PAR:DIM
24.1B EUR
44%
17%
11%
Country US
Market Cap 419.3m USD
Gross Margin
56%
Operating Margin
-118%
Net Margin
-132%
Country US
Market Cap 224B USD
Gross Margin
40%
Operating Margin
17%
Net Margin
14%
Country US
Market Cap 183.9B USD
Gross Margin
59%
Operating Margin
22%
Net Margin
20%
Country US
Market Cap 45.8B USD
Gross Margin
35%
Operating Margin
14%
Net Margin
9%
Country KR
Market Cap 59.3T KRW
Gross Margin
49%
Operating Margin
30%
Net Margin
23%
Country US
Market Cap 43.2B USD
Gross Margin
51%
Operating Margin
19%
Net Margin
18%
Country CH
Market Cap 39.4B CHF
Gross Margin
36%
Operating Margin
20%
Net Margin
10%
Country US
Market Cap 29B USD
Gross Margin
38%
Operating Margin
24%
Net Margin
20%
Country US
Market Cap 28.8B USD
Gross Margin
59%
Operating Margin
29%
Net Margin
21%
Country IE
Market Cap 27.2B USD
Gross Margin
30%
Operating Margin
13%
Net Margin
8%
Country FR
Market Cap 24.1B EUR
Gross Margin
44%
Operating Margin
17%
Net Margin
11%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Adaptive Biotechnologies Corp Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
Adaptive Biotechnologies Corp
NASDAQ:ADPT
419.3m USD
-58%
-30%
-31%
-61%
US
Thermo Fisher Scientific Inc
NYSE:TMO
224B USD
13%
6%
9%
8%
US
Danaher Corp
NYSE:DHR
183.9B USD
9%
6%
7%
6%
US
IQVIA Holdings Inc
NYSE:IQV
45.8B USD
23%
5%
10%
9%
KR
Samsung Biologics Co Ltd
KRX:207940
59.3T KRW
9%
5%
9%
6%
US
Agilent Technologies Inc
NYSE:A
43.2B USD
21%
11%
14%
14%
CH
Lonza Group AG
SIX:LONN
39.4B CHF
7%
4%
10%
8%
US
West Pharmaceutical Services Inc
NYSE:WST
29B USD
21%
16%
23%
22%
US
Mettler-Toledo International Inc
NYSE:MTD
28.8B USD
-1 261%
23%
48%
28%
IE
ICON PLC
NASDAQ:ICLR
27.2B USD
7%
4%
7%
6%
FR
Sartorius Stedim Biotech SA
PAR:DIM
24.1B EUR
12%
5%
9%
6%
Country US
Market Cap 419.3m USD
ROE
-58%
ROA
-30%
ROCE
-31%
ROIC
-61%
Country US
Market Cap 224B USD
ROE
13%
ROA
6%
ROCE
9%
ROIC
8%
Country US
Market Cap 183.9B USD
ROE
9%
ROA
6%
ROCE
7%
ROIC
6%
Country US
Market Cap 45.8B USD
ROE
23%
ROA
5%
ROCE
10%
ROIC
9%
Country KR
Market Cap 59.3T KRW
ROE
9%
ROA
5%
ROCE
9%
ROIC
6%
Country US
Market Cap 43.2B USD
ROE
21%
ROA
11%
ROCE
14%
ROIC
14%
Country CH
Market Cap 39.4B CHF
ROE
7%
ROA
4%
ROCE
10%
ROIC
8%
Country US
Market Cap 29B USD
ROE
21%
ROA
16%
ROCE
23%
ROIC
22%
Country US
Market Cap 28.8B USD
ROE
-1 261%
ROA
23%
ROCE
48%
ROIC
28%
Country IE
Market Cap 27.2B USD
ROE
7%
ROA
4%
ROCE
7%
ROIC
6%
Country FR
Market Cap 24.1B EUR
ROE
12%
ROA
5%
ROCE
9%
ROIC
6%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More